TCN 213

TCN 213 is a selective, surmountable, glycine-dependentlly GluN1/GluN2A NMDAR antagonist with IC50s of 0.55, 3.5, 40 μM in the presence of 75, 750, 7500 nM glycine, respectively. TCN 213 can be used to monitor, pharmacologically, the switch in NMDAR expression in developing cortical neurones[1][2].

Product Specifications

CAS Number

[556803-08-8]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

IGluR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/tcn-213.html

Purity

99.16

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(CSC1=NN=C(NCC2=CC=CC=C2)S1)NCC3CCCCC3

Molecular Formula

C18H24N4OS2

Molecular Weight

376.54

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

References & Citations

[1]McKay, S et al. “Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist.” British journal of pharmacology vol. 166,3 (2012) : 924-37.|[2]Edman S, et al. TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner. Neuropharmacology. 2012 Sep;63 (3) :441-9.